Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 24 of 185 for:    ERYTHROMYCIN

Effect of the Motilin Receptor Agonist, Erythromycin, on Hunger and Food Intake; Study of Role of Cholinergic Pathways

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02633579
Recruitment Status : Completed
First Posted : December 17, 2015
Last Update Posted : December 17, 2015
Information provided by (Responsible Party):
Universitaire Ziekenhuizen Leuven

Brief Summary:
In this study, the investigators will evaluate if the food intake associated with the infusion of erythromycin is caused by the phase 3 contractions or by another yet unknown effect of erythromycin. To obtain this the investigators will use atropine, a muscarinic receptor antagonist, to inhibit the formation of contractions induced by a low dose of erythromycin

Condition or disease Intervention/treatment Phase
Healthy Drug: erythromycin lactobionate Drug: Atropine Drug: Erythromycin with atropine Drug: Saline Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Official Title: The Role of Induced Phase 3 Contractions in the Control of Hunger and Food Intake
Study Start Date : October 2012
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

Arm Intervention/treatment
Active Comparator: Erythromycin lactobionate
40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %
Drug: erythromycin lactobionate
intravenous administration of erythromycin
Other Name: Erythromycin

Active Comparator: Erythromycin lactobionate with atropine
40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min
Drug: Erythromycin with atropine
intravenous administration of erythromycin with saline

Placebo Comparator: Atropine

Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min.

Infusion of saline as a placebo for erythromycin was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %

Drug: Atropine
intravenous administration of atropine

Placebo Comparator: Placebo
Infusion of saline was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; also placebo for atropine was given as an i.v. bolus of saline followed by a continuous infusion over 30 min
Drug: Saline
intravenous administration of saline
Other Name: Control

Primary Outcome Measures :
  1. Change in hunger ratings from time of administration over 6 hours [ Time Frame: 6 hours after intervention, assessment every 5 minutes ]
    visual analog scale

Secondary Outcome Measures :
  1. Timing of food intake [ Time Frame: 6 hours after intervention; up to 2 moments of food intake allowed ]
    decision to take a soup meal

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Female or male subjects aged 18 to 60
  • Subject is capable and willing to give informed consent
  • Female volunteers of child bearing potential must use oral, injected or implanted hormonal methods of contraception

Exclusion criteria:

  • Female volunteer is pregnant or breastfeeding
  • Gastrointestinal diseases, major abdominal surgery
  • Major psychiatric illnesses
  • Volunteers that use drugs affecting the gastrointestinal tract or the central nervous system
  • Allergy for macrolide antibiotics
  • Allergy for atropine
  • Severe heartburn
  • Enlarged prostate
  • Blockage of urinary tract
  • Acute closed-angle glaucoma
  • Myasthenia gravies
  • Severe heart disease
  • Thyrotoxicosis
  • Fever
  • Liver problems
  • High blood pressure or fast heart rate
  • Lung disease

Itoh Z. AI, Takeuchi S., Couch E. F., editor. Hunger contractions and motilin. 5th International Symposium on Gastrointestinal Motility; 1975; Herentals, Belgium.
Scarpellini E. HN, D. Ang, P. Vanden Berghe, I. Depoortere, J. Tack. Role of upper gastrointestinal motility stimulation in the occurence of hunger peaks. Gastroenterology. 2009;136:A330

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Universitaire Ziekenhuizen Leuven Identifier: NCT02633579    
Other Study ID Numbers: ErythromycinHungerFoodIntake
First Posted: December 17, 2015    Key Record Dates
Last Update Posted: December 17, 2015
Last Verified: October 2015
Keywords provided by Universitaire Ziekenhuizen Leuven:
Healthy volunteers
Additional relevant MeSH terms:
Layout table for MeSH terms
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Erythromycin lactobionate
Adjuvants, Anesthesia
Anti-Arrhythmia Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Gastrointestinal Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors